Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375668 | 1.00 | ALDH1A1 (0.31) | ALDH1A1MEN1LMNATSHRKMT2A | |
| SCHEMBL375060 | 0.85 | ALDH1A1 (0.34) | ALDH1A1MEN1LMNATSHRKMT2A | |
| SCHEMBL375059 | 0.85 | ALDH1A1 (0.34) | ALDH1A1MEN1LMNATSHRKMT2A | |
| SCHEMBL820502 | 0.85 | ALDH1A1 (0.34) | ALDH1A1MEN1LMNATSHRKMT2A | |
| SCHEMBL818916 | 0.83 | CHRM2 (0.33) | — | |
| SCHEMBL820866 | 0.83 | CHRM2 (0.33) | — | |
| SCHEMBL402245 | 0.83 | CHRM2 (0.33) | — | |
| SCHEMBL820263 | 0.82 | — | — | |
| SCHEMBL4467745 | 0.81 | HCRTR2 (0.36) | ALDH1A1MEN1TSHRKMT2AL3MBTL1 | |
| SCHEMBL20471851 | 0.79 | HSD17B10 (0.34) | ALDH1A1MEN1LMNATSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049563-B1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARM CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | BIRC2, BIRC7, BIRC8 | ALDH1A1 4403/4885MEN1 1628/4885LMNA 925/4885 |
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | ALDH1A1 4283/4885MEN1 1940/4885LMNA 994/4885 |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | BIRC2, BIRC7, BIRC8 | ALDH1A1 4622/4885MEN1 1589/4885LMNA 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.